Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Funding Limits Will Force Choices At Device Evaluation Office – Tillman

This article was originally published in The Gray Sheet

Executive Summary

FDA's device center says it will meet its fiscal year 2006 submission review time performance goals, but other activities might be neglected, given anticipated revenue

You may also be interested in...



Tillman Departs: Device Evaluation Director To Leave FDA March 26

Office of Device Evaluation Director Donna-Bea Tillman will step down March 26 to join Microsoft's health unit, she said in a March 1 email to her staff

Tillman Departs: Device Evaluation Director To Leave FDA March 26

Office of Device Evaluation Director Donna-Bea Tillman will step down March 26 to join Microsoft's health unit, she said in a March 1 email to her staff

MDUFMA Renewal Plan Spreads Fee Burden More Evenly; Senate Panel OKs

Just two days after FDA released its behind-schedule proposal to reauthorize the medical device user fee program, a Senate committee approved the agency's recommendations to collect almost $300 million from manufacturers through 2012

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

MT022607

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel